Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Table 7 Frequency of resource use per patient with NDM per year in France, Germany and Denmark

Health resource	France			Germany			Denmark
Health resource	BSC	Mexiletine	Difference	BSC	Mexiletine	Difference	BSC	Mexiletine	Difference
Physiotherapy	30	5	−25	24	24	0	40	40	0
Occupational therapist	10	2	−8	12	12	0	6	6	0
Speech therapy	15	2	−13	12	12	0	6	0	−6
Day case attendances	5	1	−4	4	4	0	6	0	−6

Whenever a 0 is presented, this reflects that the expert reported that they expect 0 healthcare professional visits for that resource
Key: BSC Best supportive care

ISSN: 1471-2377